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Abstract
Background and purpose Moyamoya angiopathy (MMA) is a chronic cerebrovascular disorder predominantly starting in 
childhood or early adulthood and thus affects the whole lifetime. Little is known on MMAs long-term outcomes in European 
patients. We report long-term follow-up data on Finnish MMA patients.
Methods We included patients from our Helsinki University Hospital MMA database and arranged long-term follow-up 
visits for all the patients. This follow-up included a review of the medical records accumulated in due time, detailed neuro-
logical and neuropsychological evaluation, and outcome measures modified Rankin Scale (mRS) and Barthel Index (BI).
Results There were 61 MMA patients with a mean follow-up period of 9.5 years (SD 6.7 years; range 1.3–35.4 years; 581 
patient-years). Only two patients had died and two-thirds (n = 40, 65.6%) had no new events during the follow-up period. 
Eight patients (13.1%) had an ischemic and five patients (8.2%) a hemorrhagic stroke during the follow-up. There were no 
differences between operated (n = 26) and conservatively (n = 35) treated groups regarding recurrent events or the outcome 
measured with mRS or BI. Finnish MMA patients reported significantly poorer physical and psychological health aspects 
of QOL when compared to the general Finnish population. Symptoms of low mood were found in 27 (56%) patients.
Conclusions Finnish MMA patients have a benign and stable course with a ~3.5 % annual stroke risk. We found no differ-
ences in the clinical outcomes between the operated and conservative groups, however, the psychosocial well-being requires 
more attention in MMA patients.
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Introduction
Moyamoya angiopathy (MMA) is a rare progressive steno-
occlusive cerebrovascular disorder mostly affecting the ante-
rior circulation, and more specifically the distal portion of 
the internal carotid artery and its distal branches, and only 
occasionally the posterior circulation. Insidious occlusion of 
the anterior circulation cerebral arteries leads to formation 
of the characteristic abnormal vascular networks, i.e. the 
moyamoya vessels [1]. MMA is a chronic disorder starting 
in childhood or early adulthood with a clear dominance in 
females, leading to a life-long affection. Although MMA is 
less frequent in Europe, accumulating evidence suggests it 
to be substantially more common than previously believed. 
Germans have done studies in their patient population con-
cerning recurrent stroke risk in surgically and conservatively 
treated patients [2], and efficacy of STA–MCA bypass sur-
gery in Caucasian patients [3]. Despite this, the natural 
course of the disease, i.e. its long-term events and outcomes, 
as well as patients’ quality of life and state of mood, are not 
thoroughly studied in the other European populations.
After establishing the Helsinki University Hospital-
Moyamoya Angiopathy (HUH-MMA) database including 
61 Finnish origin MMA patients [4], we arranged a prospec-
tive follow-up study of our patients. Our aim was to find out 
the long-term consequences and prognostic characteristics 
of the Finnish MMA population including the vocational 
outcomes considering the young age of most of the patients, 
and self-reported quality of life (QOL) and state of mood.
Materials and methods
This study was performed at the Departments of Neurol-
ogy and Neurosurgery, in Helsinki University Hospital 
(HUH), Helsinki, Finland. The local ethics committee 
approved the study (154/13/03/00/10). All MMA patients 
who agreed to come for an outpatient clinical follow-up 
visit gave a written consent. For registry-based data collec-
tion, Finnish legislation does not require patient consent.
We searched for all diagnosed moyamoya disease (MMD) 
and moyamoya syndrome (MMS) patients referred to our 
hospital and collected the patient data into a detailed data-
base as reported earlier [4] and called them for a face-to-face 
follow-up visit. Our HUH-MMA database includes detailed 
data on the patient’ medical history, family history of stroke 
and MMA, medication on admission and preventive medica-
tion at discharge, hospital admission data, clinical manifes-
tation and time course, treatment and procedures, discharge 
details, laboratory tests on admission, radiological data, all 
deaths, vascular deaths, and causes of deaths in detail.
This was a cross-sectional clinical follow-up study. The 
follow-up data of the deceased patients and of those who 
wished not to participate in the study were followed-up from 
the death certificates and hospital records. All consenting 
patients were personally interviewed by an experienced neu-
rologist (MS). The follow-up period started after the patient 
had visited the hospital for the first time due to the MMA-
related symptoms and ended at the end of September 2015 
when the hospital charts were last checked.
The clinical examination at the follow-up visit included 
the National Institutes of Health Stroke Scale (NIHSS) score, 
modified Rankin Scale (mRS), and Barthel Index (BI). The 
working status (employed/working/studying, permanent dis-
ability pension, retired due to age, sick leave) was recorded. 
A new stroke, any other new diagnosis after the MMA diag-
nosis, the medication, surgical operations, perioperational 
complications, and family history of strokes or MMA were 
recorded, based on the interview and the medical records.
We defined progression of the disease as a new ischemic 
or hemorrhagic stroke after the primary hospital admission 
or any worsening in a stenotic vessel according to visual 
examination of the angiography images and development of 
stenosis in a vessel that was normal-looking in the previous 
images. Favorable outcome was defined as mRS 0–2 and an 
excellent outcome as mRS 0–1.
Questionnaires concerning the quality of life and the pro-
file of mood were sent to the patients by mail. The patients 
returned the filled questionnaires at the beginning of the 
comprehensive neuropsychological examination. The ques-
tionnaires were checked after the enquiry and completed 
together with the patient if there were missing items. A 
psychologist (AMU), familiar with the neuropsychological 
assessment procedure, conducted all neuropsychological 
examinations and she was blinded to the current clinical 
neurological and neuroradiological data.
Quality of life
WHOQOL-BREF has been used worldwide in diverse 
diseases and conditions to measure the quality of life [5]. 
WHOQOL-BREF includes 26 items and four domains: 
physical health, psychological health, social relationships, 
and environment [6]. The items are computed to four sepa-
rate domains and separately scaled from 0 to 100, where 0 
is the worst possible score and 100 the best. The question-
naire also includes questions of perceived health in general 
(how satisfied are you with your health?) and quality of life 
in general (how would you rate your quality of life?). The 
questionnaire has a 5-point Likert-scale (1 = very poor to 
5 = very good). Perceived quality of life in MMA patients 
was compared to a Finnish population-based sample survey 
[7].
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Mood state
Modified profile of mood states (POMS) questionnaire was 
used to assess patients’ mood symptoms [8, 9]. We used 
a total score of the modified version of the POMS that 
includes 38 adjectives rated on a 5-point Likert scale (0 = not 
at all to 4 = very much). Patients were asked to circle adjec-
tives which describe feelings and emotions during last week 
[9]. The characteristics of the controls of a previous Finnish 
study [10] were used to determine a cut-off point for elevated 
mood in our MMA patients. The elevated mood was deter-
mined as POMS score higher than 41.4 (i.e. 75 percentile of 
the control group, unpublished data).
Statistical analyses
Continuous data are reported as mean ± SD. All statistical 
analyses were done using the SPSS software (IBM Corp. 
Released 2012. IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp.). We compared two groups: 
those treated with a revascularization by-pass operation to 
those treated conservatively using Crosstabs function and 
Kaplan–Meier. Actual annual stroke risk with 95% confi-
dence intervals (CI) was calculated with the Life tables func-
tion using the formula 1 − [(1 − Ic)1/n], with Ic as cumulative 
incidence rate and n as the number of years. Quality of life 
and mood symptoms were compared between by-pass oper-
ated and conservatively treated patient groups using an inde-
pendent sample T test with 95% confidence. One sample T 
test was used to compare MMA patients QOL with a Finnish 
population-based sample survey [7]. A two-sided probability 
(P) value of 0.05 or lower was considered significant.
Results
All 61 patients were followed-up. Two patients died during 
the follow-up period and four patients either did not want 
to participate or could not be reached. Their death certifi-
cates and medical records were analyzed. Fifty-five patients 
came to the follow-up visit. The data were obtained by inter-
viewing the patients and their relatives, as well as by going 
through the medical records. The mean age at the start of 
the follow-up was 35 (SD 17; range 3–77). Most patients 
(n = 50, 82%) were women. The mean follow-up period was 
9.5 years (SD 6.7 years; range 1.3–35.4 years). Patient-years 
summed up to 581.
Mortality Two female patients died during the follow-
up period. Neither of them was using antiplatelet ther-
apy. One of them was diagnosed with MMD at the age 
of 50 years after an intraventricular hemorrhage. A year 
later she underwent bilateral revascularization surgery 
(STA-MCA + EDAMS). She died 4 years later after a new 
intracerebral hemorrhage (ICH). The second patient was 
diagnosed at the age of 19 after a transient ischemic attack. 
On digital subtraction angiography bilateral internal carotid 
artery occlusion and moyamoya collateral network were 
detected. At the age of 47 and 48 she had vertigo and bal-
ance problems and imaging showed microhemorrhages as 
well as typical bilateral MMA vessel abnormalities. She died 
at the age of 53 because of ICH.
New vascular events Two-thirds (n = 40, 65.6%) of the 
patients had no new vascular events. Eight patients (13.1%) 
had an ischemic and five patients (8.2%) had a hemorrhagic 
stroke during the follow-up. The average annual rate of a 
recurrent stroke from the first event for all study subjects was 
3.5%. There were no differences between the operated and 
the conservatively treated patients in the stroke recurrence 
risk. In seven patients (11.5%) we detected asymptomatic 
progression in their vascular stenosis. During the follow-
up period, one of the unilateral MMS patients progressed 
to bilateral MMS. Three out of 8 (37.5%) patients initially 
presenting with a hemorrhagic stroke had a new hemor-
rhagic event during the follow-up, and 6 out of 31 patients 
(19.4%) initially presenting with an ischemic stroke had a 
new ischemic stroke during the follow-up (Table 1).
Neurological outcomes The mean NIHSS at follow-
up was 1 and median 0. The mean/median mRS at fol-
low-up was one. The follow-up examination was done 
0.2–11.7 years after recurrent strokes, in 12 patients. Func-
tional outcome was favorable (80%) or excellent (71%) in 
most of the patients. There was no difference in the outcome 
between the operated (n = 26) and conservatively treated 
(n = 35) patients, when measured with mRS or BI. The mean 
BI at follow-up was 97 (SD 12) and median 100 (min 25). 
Only 10% of the patients required assistance in activities of 
daily living.
Surgical treatments Twenty-six patients underwent revas-
cularization surgery. The techniques used are reported in 
detail previously [4]. One patient had an intraoperative com-
plication, a small arterial wall laceration. There was one 
postoperative hematoma which was treated conservatively. 
However, this patient was later shunted for communicating 
hydrocephalus. Three patients had wound healing problems.
Medical treatments 70% of the conservatively treated 
patients used antiplatelet or anticoagulation (n = 1) therapy 
and 69% of the operated patients used antiplatelet therapy 
at the follow-up visit [4].
Vocational outcomes and psychosocial factors More than 
half (59%) of the patients were working, while 32% were on 
a permanent disability pension due to MMA, 5% had retired 
due to age, and 3% were on sick leave at the follow-up visit.
Quality of life The WHOQOL-BREF questionnaire was 
available for 48 MVV patients. The patients reported sig-
nificantly poorer physical health and psychological health 
aspects of QOL and a trend for poorer environmental 
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Table 1  Presenting data on MMD patients with new vascular events during the follow-up period
CI Cerebral infarction, ECA–MCA external carotid artery–middle cerebral artery bypass, EDAS encephalo-duro-arterio-synangiosis, EDAMS 
encephalo-duro-arterio-myo-synangiosis, F female, ICH intracerebral hemorrhage, IVH intraventricular hemorrhage, M male, MMD moyamoya 
disease, MMS moyamoya syndrome, mRS modified Rankin Scale, SAH subarachnoid hemorrhage, STA–MCA superficial temporal artery–middle 
cerebral artery bypass, TIA transient ischemic attack
*Old bleed appeared on follow-up imaging, but has been asymptomatic
**Operated after our follow up visit















M 1959 MMD defini-
tive
IVH 1998 113 SAH 2007 1
M 1975 MMD unilat-
eral
CI 1983 26 CI 2009 0
M 1957 MMD defini-
tive
Seizure 2006 Progression of 
stenosis
0
F 1986 MMD defini-
tive
CI 2013 Progression of 
stenosis
2
F 1988 MMS (Down) Stenosis l.sin Stenosis l. dx EDAS l. sin. 2006 –
F 1958 MMD defini-
tive
ICH 2003 101 ICH 2011 2 STA–MCA bilat-
eral 2004
ICH
F 1960 MMD defini-
tive
CI 2013 7 CI 2014 0 ** –
F 1965 MMD defini-
tive





F 1965 MMD defini-
tive
CI 2004 CI × 2 2005, 2009 1
F 1959 MMD defini-
tive
CI 1983 268 CI (dg) 2005 2
F 1985 MMD defini-
tive
CI 2008 Progression in 
stenosis
2013 0 **
F 1959 MMD defini-
tive
IVH 2009 50 ICH 2014 6 (2014) STA–
MCA + EDAMS 
bilateral 2010
ICH 2014
F 1959 MMD defini-
tive
TIA 1978 431 ICH 2013 6 (2013)
F 1971 MMD defini-
tive
CI 1995 99 CI 2003 1
F 1966 MMD defini-
tive
CI 2006 33 CI 2009 2 STA–MCA 2006, 
2007
CI 2009
F 1996 MMD defini-
tive
CI 2005 Progression in 
stenosis on 
left
2006 0 EDAS l. dx. 2005, 
l. sin 2006
–
F 1986 MMD defini-
tive
CI 2006 12 Progression in 
stenosis on 
left
2008 1 STA–MCA l. dx. 





F 2001 MMD defini-
tive
CI 2009 Post. op. TIA 0 EDAMS 2009 
l. dx
TIA
F 1969 MMD defini-
tive
SAH 1998 Progression of 
stenosis
2005 1
F 1970 MMD defini-
tive
CI 2013 15 1 STA–MCA l. dx. 
2013, l.sin. 2014
–
F 1983 MMD unilat-
eral
Seizure 2002 Progression of 
stenosis
2006 0 ECA–MCA l.dx. 
2003
–
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aspects of the QOL when compared to the Finnish popu-
lation-based sample survey (Table 2).
The surgically treated patients reported better social 
relationship aspects of QOL compared to conservatively 
treated patients (mean ± SD 81.0 ± 17.2 vs. 69.7 ± 19.2; 
P = 0.04). There were no significant differences in the 
other three subdomains (physical, psychological, and envi-
ronmental domains) of QOL, however, the working MMA 
patients estimated their physical, psychological, and social 
aspects of QOL to be better than patients on sick leave or 
pension (Table 3).
Mood state POMS was obtained from 48 MMA patients. 
Mean POMS total score was 45.4 ± 24.5. Symptoms of low 
mood were found in 27 (56%) patients, using a cut-off 
point of 41.4 points derived from the scores of the previ-
ous Finnish study [10]. Surgically- and conservatively-
treated patients did not differ significantly in POMS total 
score (39.3 ± 25.4 vs. 50.1 ± 23.2; P = 0.13). Working sta-
tus (i.e. work, sick leave, and pension) was not associated 
with patients’ mood symptoms.
Discussion
We prospectively collected detailed follow-up and outcome 
information on all the 61 Finnish MMA patients diagnosed 
and included in our registry. During a total of 581 patient-
years, two patients had died (due to ICH), 13.1% (n = 8) 
had an ischemic and 8.2% (n = 5) a hemorrhagic stroke, and 
42.6% (n = 26) had undergone revascularization surgery, 
while two-thirds (65.6%) had no new vascular events. Func-
tional outcome was favorable in 80% and excellent in 71% of 
the patients. 55% of the patients were working at the time of 
the follow-up visit. There was no difference between patients 
with surgical treatment vs. those treated conservatively con-
sidering the NIHSS, mRS, BI, mood symptoms, or working 
status at the follow-up visit. MMA patients showed poorer 
QOL measures compared to healthy control subjects.
There are not many systematic, long-term follow-up stud-
ies of MMA patients, making it difficult to reliably inform 
the patient and their families about prognosis, develop 
prognostic scores, estimate the best preventive approaches, 
or suggest more aggressive treatments in patients who are 
expected to have a poor outcome. Furthermore, the char-
acteristics of MMA disease seem to be different in various 
patient populations with different ethnical backgrounds [11]. 
The major studies reporting long-term outcomes of MMA 
patients have included 1146 [12], 104 [13], and 101 [14] 
patients with 5.2–9 years, 29–46 months, and 26.5 months 
of follow-up time reported.
In a small German study the mortality rate was 9.5% 
(2 patients) during a mean follow-up period of 3.7 years 
[2]. In a study from the United States the overall mortal-
ity rate after surgical revascularization was 2.3% during a 
mean follow-up period of 4.9 years in 233 adult and 96 child 
MMA patients [15]. In a Korean study with a mean follow-
up of 82.5 months the mortality rate was 6.5% and the cause 
of death in all four cases was recurrent hemorrhage [16]. 
Our 3% mortality during a 9.5-year period (mean follow-
up) is partly in line with these, or even less than that in the 
Table 2  Differences in quality of life scores between the patients with 
MMA and Finnish population-based sample [7]
WHOQOL-Bref = Quality of life scales [6]
*One sample T test
WHOQOL-BREF MMA patients 
N = 48, mean 
(SD)
Sample survey 
N = 4306, mean 
(SD)
P value*
Physical domain 66.7 (21.9) 77 (17.4) 0.002
Psychological 
domain
64.9 (18.9) 74 (14.4) 0.002
Social relationship 74.6 (19.0) 79.0 (16.8) 0.119
Environmental 
domain
72.2 (17.5) 77 (12.9) 0.067
Table 3  Differences in quality 
of life and mood symptoms 
between the working MVV 
patients and patients at sick 
leave or pension
POMS = Profile of Mood States [8]
WHOQOL-Bref = Quality of Life Scales [6]
*Independent samples T test
Psychosocial functioning Currently at work life
N = 29, mean (SD)
Sick-leave or pension
N = 19, mean (SD)
P value*
WHOQOL-BREF
 Physical domain 75.3 (17.7) 53.5 (21.3) 0.000
 Psychological domain 71.0 (15.9) 55.7 (19.7) 0.005
 Social relationship 79.4 (15.0) 67.4 (22.4) 0.032
 Environmental domain 76.2 (16.6) 66.2 (17.5) 0.288
POMS [6, 7] 42.3 (26.9) 50.0 (20.1) 0.295
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previous studies. Interestingly, ICH appears to be the main 
cause of death in all published series.
In the Korean population, the reported annual risk of 
stroke was 4.5%/person-year, with 5- and 10-year cumulative 
risks of any stroke being 17% and 30%, respectively [16]. 
Furthermore, patients presenting with a hemorrhagic event 
tended to show a higher incidence for a recurrent hemor-
rhage and patients with ischemic symptoms had a higher rate 
of recurrent ischemia [16] which is in line with our results. 
One Japanese study reported the recurrence rate for cerebral 
infarction to be lower in the surgery group than the non-sur-
gery group, although the rate of infarction was not different 
between the antiplatelet and the non-antiplatelet subgroup 
[12]. They also found no difference in the recurrence rate 
of cerebral hemorrhage in patients whose initial symptom 
was hemorrhage when treated surgically or conservatively 
[12]. In a Chinese study, the investigators found the annual 
rebleeding rate to be 2.2% following encephaloduroarterio-
synangiosis operation in 95 MMV patients during a median 
follow-up of 8.5 years [17]. Another Korean study found that 
86% of adult MMD with conservative management did not 
develop recurrent ischemic stroke after an ischemic stroke 
when 90% of the patients used antiplatelet medication [13]. 
Our results are in line with this Korean study. In a German 
MMA patient population (n = 21) the 5-year-Kaplan–Meier 
risk for recurrent stroke was 80.95%. 11 patients (52.3%) 
had the neurosurgical revascularizing procedure done and 
the Kaplan–Meier risk of perioperative or subsequent stroke 
was 27.27% within the first month and was stable thereafter. 
They found no significant difference in the number of strokes 
between surgically and medically treated patients [2].
In the German study, 68.4% of 21 patients did not have 
significant long-term disability (mRS 0 or 1) [2]. In the 
American revascularization study the mean mRS was 0.83 at 
the mean follow-up of 4.9 years [15]. In the Korean study 
mRS was 1.3 ± 1.4 after 82.5 months of follow-up [16]. Our 
results are in good line with all of these existing reports. In 
general, MMA appears to affect the patients mildly both in 
Asian and Western populations including our Finnish patient 
population.
Extracranial–intracranial by-pass operation is usually 
considered to be the treatment of choice for MMA patients 
presenting with ischemic stroke, despite a lack of firm evi-
dence [12, 18]. For hemorrhagic stroke the evidence is even 
less clear, although the JAM trial suggested a statistically 
marginal preventive effect of direct bypass against rebleed-
ing [19], especially for patients with posterior circulation 
region hemorrhages [20]. In a recent meta-analysis based 
on Asian patient series, surgical revascularization was 
superior to conservative treatment in reducing the rate of 
recurrent stroke events including both ischemic and hemor-
rhagic events but not in reducing mortality [21]. Another 
recently published meta-analysis mainly including articles 
concerning studies done in Asian populations, also two 
articles including two Caucasian MMA patient popula-
tions, found that surgery significantly decreased the future 
stroke events compared to conservative treatments in adult 
MMD [22]. A third meta-analysis including mainly studies 
in Asian, but also five Caucasian populations, found that the 
surgical treatment significantly reduced the risk of stroke 
and according to subgroup analysis the surgical treatment 
was more beneficial in hemorrhagic MMD [23]. In a Ger-
man study of 54 Caucasian MMA patients, where all patients 
underwent STA–MCA bypass operation and were followed-
up for 38.2 months thereafter, nearly all patients remained 
symptom-free from ischemic strokes, hemorrhages, and 
microbleeds. The authors, therefore, considered bypass 
surgery safe and effective in Caucasian MMA patients [3]. 
Antiplatelet therapy is commonly used for patients initially 
presenting with ischemic symptoms [24] despite lack of evi-
dence for its efficacy [12]. It is often difficult to predict the 
clinical course of a single patient, and therefore, makes it 
difficult to recommend either operation or antiplatelet treat-
ment without firm evidence.
Among our patients, those who did not receive by-pass 
operation were either severely handicapped due to a stroke, 
or were nearly symptom-free, and therefore, not willing to 
take a potential risk of surgery. One-third of our patients 
had not been referred to neurosurgical consultation at all, as 
some physicians have doubts on efficacy and safety of surgi-
cal treatment because of the lack of published randomized 
studies. These various factors create a significant selection 
bias making the surgery and conservative treatment groups 
even less comparable. While surgery is often offered after 
clinical judgement the evidence for surgery is fairly weak. 
In the future, however, larger multicenter datasets will help 
to compare conservative and surgery-treated patients with 
baseline characteristics being adjusted with a propensity-
score approach and deliver better-quality data for designing 
randomized trials.
Vocational outcomes in MMA patients have not been 
published earlier. Our study shows that despite our patients 
being fairly young, only 59% could return to work, and even 
one-third (32%) became disability-pensioned despite good 
mRS and BI scores. These findings require precise evalua-
tion for the exact cause of disability to seek possible inter-
ventions and suitable employment strategies for the young 
MMA patients. Cognitive decline occurring over several 
years often attributed to chronic hypoperfusion is often sug-
gested in MMA patients, but has not yet been adequately 
investigated.
Our MMA patients estimated their QOL less satisfying 
in physical and psychological domains when comparing to 
the Finnish population-based sample [7]. This finding is in 
line with previous results reporting that chronic diseases (i.e. 
stroke or other neurological diseases) are known to diminish 
580 Journal of Neurology (2019) 266:574–581
1 3
the QOL [5, 25]. It has been suggested that the awareness 
of MMD may develop severe disturbances in performance 
and could be the main reason for psychological symptoms 
caused by MMD [26]. QOL was perceived lower among 
those MMA patients who were currently not working when 
compared to those who were in work life. Our finding is 
in line with a study where better QOL and fewer signs of 
low mood were associated with return to work after a mild 
stroke [27].
So far there is no curative treatment to MMD itself and 
the uncertainty of the progress of the disease may raise 
doubts about patients’ well-being and health in the future. 
Long-term depressive symptoms [28, 29] as well as dimin-
ished QOL [28–30] are frequently found among stroke 
patients. In this study, symptoms of low mood were found 
in slightly over half (56%) of Finnish MMA patients. How-
ever, the working status was not significantly related to a 
perceived state of mood among MMA patients. In previous 
studies MMA patients’ reported mood symptoms have been 
slightly lower compared to our study. Almost one-third of 
MMD patients in the Karzmark et al. study expressed symp-
toms of low mood, namely depression (28%) and anxiety 
(29%) [31]. In the study of Festa et al. 28% of the MMD 
patients developed moderate or severe depression [32].The 
slight differences in the frequencies of mood symptoms 
between these studies and our study may be explained by 
the differences in methodology. The mood scale in our study 
taps general symptoms, whereas in earlier studies more diag-
nostic measures have been used.
MMD itself may be responsible for depression and 
reduced QOL [26]. Caucasian patients with MMD are at a 
considerably higher risk of future strokes, even though the 
risk appears to abate over time [33]. These issues may have 
an impact to perceived QOL, as well as experienced state of 
mood in MMA patients. Psychological factors in chronic dis-
eases like MMA affect the general well-being and may com-
plicate the medical care. QOL is important to assess already 
during the diagnostic process and especially when treatment 
and rehabilitation are planned. So far, the impact of psycho-
social factors has not been fully understood among MMA 
patients, although it seems that these factors are important 
for subjective well-being and have an impact even on the 
work status. In the future, we need larger, well-designed 
longitudinal studies to fully understand the consequences 
of MMA in patients from various geographies to gain better 
insight into the disease and hopefully its treatments.
Our study has several merits. First, we could include 
all diagnosed patients within our catchment area, closely 
approaching to the population-based setting. We investigated 
the patients in detail, both retrospectively and prospectively. 
Almost all patients were personally met and examined by a 
neurologist. We had a rather long follow-up time. Further-
more, the patient population is homogeneous all being of 
Finnish origin and living in Finland. However, we are also 
aware of some limitations. The number of patients is mod-
estly reflecting the rarity of MMA in European populations.
Our study indicates a relatively benign course of MMA in 
the long run in Finnish patients, but only slightly over half 
of the patients were actively working. Multicenter prospec-
tive long-term follow-up studies and randomized trials with 
substantially larger patient numbers are needed in the future 
to obtain more vigorous data and to test the benefits of vari-
ous treatment approaches.
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